Save the date next month and RPL will see you for the American College of Clinical Pharmacologys (ACCP) 39th Annual Meeting taking place 12th to 14th September 2010 in Baltimore, Maryland.

The Annual Meeting will cover a wide array of topics such as international drug development and collaboration, pharmacometrics, pharmacogenomics, and specific sessions relating to biologics, nutraceuticals, and drug therapy in special populations, providing an ideal platform for scientists of various disciplines to meet and discuss areas of common interest.

We invite you to come down and see us at our booth that will be located in Harborside DE zone at the Baltimore Marriott Waterfront Hotel. In addition we are pleased to announce that Dr Jorg Taubel, MD., FFPM., Clinical Pharmacologist and Principal Investigator at Richmond Pharmacology, is due to present at the Annual Meeting where he will address two core topics of discussion, namely:

  • 132 - Repeated Dosing of Strontium Ranelate 4G Over 15 days Does Not Prolong QTC Interval in Healthy Volunteers
  • 133 - PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity  

Dr Taubel�s presentation has been scheduled for Poster Session 2 on Monday, 13th September, 2010 from 6 PM � 7:30 PM and there are also a number of other learning activities in store, so be sure not to miss out on what is expected to be both an educational and rewarding conference.

For more information on the Annual Meeting click here for further details or click here to view the preliminary meeting program.

We look forward to seeing you next month in Baltimore!

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event